#China #Hangzhou #Forbes China #Tigermed #Go-International

Tigermed's Stellar Recognition in 2025

Tigermed, a renowned clinical development services provider, has recently been honored by Forbes China as one of the Top 30 companies in the "2025 Forbes China Go-International Flagship Brands" list. This recognition reflects not only Tigermed's impressive growth but also highlights the increasing global influence of biopharmaceutical innovation originating from China.

In 2023, Forbes China initiated the Go-International ranking to spotlight companies making significant strides in expanding their operations overseas. The latest iteration of this list categorizes firms into four distinct groups: Flagship Brands, Leading Brands, Investment Value Brands, and Leading Figures. The Flagship Brands category, where Tigermed proudly stands, comprises large, well-established companies recognized for their extensive international presence.

Tigermed's Global Presence

With over 180 offices and networks across various continents including North America, Europe, Asia-Pacific, Africa, and Latin America, Tigermed has established itself as a key player in the biopharmaceutical landscape. Employing more than 10,000 staff members worldwide, the company is committed to creating an integrated end-to-end platform that drives innovation and development in the healthcare sector. This platform aims to bridge the gap for China's biopharmaceutical sector as it ventures into international markets.

One of the primary objectives highlighted by Tigermed is to strengthen partnerships within the industry. By doing so, the company aims to further its mission of enhancing the quality of healthcare solutions on a global scale. This involves not only developing research-driven medical solutions but also ensuring that they cater effectively to diverse patient needs worldwide.

Looking Ahead: Expanding Global Footprint

Tigermed has articulated a clear vision for its future path, focusing on maintaining its momentum in global expansion. The company plans to enhance its localization efforts and accelerate its digital transformation initiatives. This strategic approach is designed to support the rising international demand for innovative healthcare solutions.

The company's commitment to deepening industry partnerships is expected to foster advancements in China's pharmaceutical landscape. By collaborating closely with various stakeholders, Tigermed aims to deliver groundbreaking and high-quality healthcare solutions, contributing positively to patient outcomes globally.

For those looking for more insights into the 2025 Forbes China Go-International Flagship Brands selection, detailed information can be accessed through their official announcement on WeChat.

About Tigermed

Tigermed (Stock code 300347.SZ/3347.HK) stands at the forefront of providing integrated research and development solutions tailored for the biopharmaceutical and medical device sectors. With a diverse array of services encompassing everything from preclinical development to clinical trials and commercialization, Tigermed collaborates with over 3,600 clients, ensuring that its offerings are not only efficient but also cost-effective.

The company's global workforce spans across more than 180 locations, embodying its commitment to leveraging an expansive network that addresses the evolving needs of healthcare industries worldwide. Tigermed prides itself on a mission to fulfill unmet patient needs and ultimately save lives through its innovative solutions.

To explore more about Tigermed's offerings and its commitment to advancing healthcare, visit www.tigermedgrp.com.

In conclusion, Tigermed's recent accolade positions it as a significant contributor to international healthcare innovations and reiterates its dedication to bridging healthcare needs across borders.